Why "Wegovy Click Charts" Are a Bad Idea, and What to Do Instead

• Explains plainly why click counting is guesswork rather than measurement
• Covers splitting, microdosing and stretching, and what each actually does
• Sets out what the MHRA says about unlicensed and falsified products
• Gives a practical route for anyone finding treatment hard to afford

If you have searched for a Wegovy click chart, you are almost certainly not being reckless. You are most likely trying to make treatment that is working stretch further than your budget allows, and that is a reasonable problem to have.

This page will not give you a click chart, and it will explain exactly why rather than simply refusing. The short version is that click counting is not a way of measuring a smaller dose. It is a way of guessing, with a number attached that makes the guess feel precise.

The longer version, and the more useful one, is that the problem underneath the search has real answers, and they are not the one you were looking for. Those answers are at the end of this page.

Key things to know

• A pre-filled pen is designed to deliver fixed doses. It is not a measuring instrument for partial ones.
• Click charts circulating online are not produced or verified by anyone accountable, and there is no way to check what you actually received.
• Stretching a dose does not reliably give you a smaller dose. It gives you an unknown one.
• The MHRA warns that products bought without a prescription may not contain what you think and could be contaminated.
• If cost is the problem, say so at your review. There are legitimate options, and a prescriber cannot offer them if they do not know.

What a click chart claims to do

The idea is that because a Wegovy pen makes an audible click as the mechanism moves to administer the active ingredient semaglutide, you can count clicks to deliver a fraction of a dose, and thereby get more doses out of a pen than it was designed to give. This practice is sometimes sought by patients trying to stretch their medication supply due to cost concerns.

It sounds plausible and is often presented as straightforward arithmetic. The charts that circulate look authoritative, with tidy rows and confident numbers representing dose strengths such as 0.25 mg or 2.4 mg. However, none of that makes it a reliable or safe dosing method.

Using a click chart can lead to inaccurate dosing. This may affect how well Wegovy works and could increase the risk of side effects. The prescribed dose-escalation schedule is designed to help the body adjust to semaglutide and improve tolerability. Changing the dose without medical guidance can make side effects and treatment response harder to predict.

Patients should always follow the exact Wegovy dosage and dosing schedule recommended by their doctor or pharmacist, including the starting dose and maintenance dose, to ensure safe and effective treatment. This includes understanding what to do if a dose is missed or if a dose is taken early or a double dose is accidentally administered. The pen doses are pre-set to deliver specific amounts of semaglutide, and partial doses are not supported.

Why this page does not include a click chart

Three reasons, and each is sufficient on its own.

The pen is not a measuring device

The Wegovy FlexTouch pen is designed to deliver the prescribed dose shown on its dose counter. Although the dose selector makes audible clicks, these clicks are not a reliable way to measure or calculate a partial dose. The manufacturer's instructions specifically advise against setting the dose by counting clicks.

You cannot verify what you actually received

This is the part that matters most and the part click charts never address.If you try to administer a partial dose by counting clicks, you cannot reliably establish how much medicine you have delivered using that method. The dose may differ from what you intended, making it harder to judge treatment effectiveness and manage side effects safely.

That uncertainty runs in both directions. You might have taken considerably less than intended, in which case you are having the inconvenience of Wegovy treatment without much of the effect. You might have taken considerably more, in which case the unpleasant few days that follow, such as stomach pain or nausea, will be blamed on the medicine rather than on the method.

The numbers in circulation come from nowhere accountable

Click charts are not produced by regulators, Novo Nordisk, prescribers, or any official source. They are produced by people, shared, copied, altered in the copying, and passed on with the original caveats stripped out.

There is no version control, no correction mechanism, and nobody accountable if a figure is wrong. A chart that has been through six re-posts is not data. It is a rumour with a table around it.

If the real question is whether there is a treatment that fits your circumstances, that is a conversation worth having about licensed Wegovy treatment options rather than a problem to solve with a spreadsheet. Treatment suitability depends on an individual clinical assessment, including consideration of factors like excess weight and body adjustments to the hormone.

Can you split a Wegovy pen or dose?

No, and a prescriber will not support it. The pen is licensed to deliver the doses it was designed to deliver, and using it any other way puts you outside the terms on which the medicine was assessed and approved.

That is not a technicality about paperwork. The licence is the thing that connects the medicine in your hand to the trial evidence that showed it worked and the safety review that cleared it. Step outside it and none of that evidence describes what you are doing any more.

What about microdosing?

The word makes it sound like a considered protocol. It is not. There is no licensed microdosing regimen for this class of medicine in the UK, no product information describing one, and no clinical trial evidence establishing what such a regimen would do.

Any request to use a medicine outside its licence gets the same answer here: no, and the reason is that nobody, including the people recommending it online, knows what the outcome will be.

The pen is not a measuring device

A pre-filled pen is engineered to deliver a specific, fixed amount of semaglutide and then stop. The mechanism inside it is designed around that single job. It is not designed, tested or approved to deliver a fraction of that amount accurately, and nothing about it was built with partial delivery in mind.

A click is a mechanical noise made by a moving part, not a calibrated unit of medicine like the mg dosage indicated on the pen. Treating it as one is like measuring flour by counting how many times the bag rustles. Remove the pen cap before use and replace it after the injection. Always remove the used needle and store the pen without a needle attached, following the manufacturer's instructions, to help prevent contamination, leakage and inaccurate dosing.

Wegovy is administered as a once-weekly injection using the pen, and the dose is carefully determined by a healthcare professional to match your treatment plan. This dose escalation schedule typically starts at 0.25 mg and increases gradually, allowing your body to adjust to the medication and reduce side effects such as nausea or stomach pain.

It is critical to follow the prescribed dosing schedule, which includes instructions on what to do if you miss a dose, take a dose early, or need to skip an injection. Wegovy dosing depends on the specific product, indication and treatment plan. In the UK, 2.4 mg once weekly has been the established maintenance dose for weight management, and a 7.2 mg once-weekly option is now also authorised for eligible adults under the applicable prescribing guidance. Do not increase your dose or change how you use your pen without advice from your prescriber.

The pen contains four doses, each intended for one week, and should be discarded six weeks after first use.

A reduced calorie diet and increased physical activity are recommended alongside Wegovy treatment to support weight loss and overall health. Not everyone responds the same way to the medication; some may experience side effects that improve within a few weeks as the body adjusts. If you have common questions about injection technique, needle use, or managing side effects, your healthcare provider can help determine the best approach.

You cannot verify what you actually received

This is the part that matters most and the part click charts never address. If you deliver a partial dose, there is no way to know what went in. Not approximately, not by feel, not by looking at the pen afterwards.

That uncertainty runs in both directions. You might have taken considerably less than intended, in which case you are having the inconvenience of treatment without much of the effect. You might have taken considerably more, in which case the unpleasant few days that follow will be blamed on the medicine rather than on the method.

The numbers in circulation come from nowhere accountable

Click charts are not produced by regulators, manufacturers or prescribers. They are produced by people, shared, copied, altered in the copying, and passed on with the original caveats stripped out.

There is no version control, no correction mechanism and nobody accountable if a figure is wrong. A chart that has been through six re-posts is not data. It is a rumour with a table around it.

If the real question is whether there is a treatment that fits your circumstances, that is a conversation worth having about licensed treatment options rather than a problem to solve with a spreadsheet. Treatment suitability depends on an individual clinical assessment.

Can you split a Wegovy pen or dose?

No, and a prescriber will not support it. The pen is licensed to deliver the doses it was designed to deliver, and using it any other way puts you outside the terms on which the medicine was assessed and approved.

That is not a technicality about paperwork. The licence is the thing that connects the medicine in your hand to the trial evidence that showed it worked and the safety review that cleared it. Step outside it and none of that evidence describes what you are doing any more.

What about microdosing?

The word makes it sound like a considered protocol. It is not.There is no established, licensed Wegovy regimen based on counting pen clicks to deliver unapproved partial doses. The approved dosing instructions should be followed, and any proposed dose reduction or change to the treatment schedule should be discussed with a prescriber.

Any request to use a medicine outside its licence gets the same answer here: no, and the reason is that nobody, including the people recommending it online, knows what the outcome will be.

What actually happens when you stretch a dose

Three things, none of which is what people hope for.

You can get the side effects without the benefit

The gastrointestinal effects of this class are common. The MHRA notes they may affect more than one in ten patients, with nausea, vomiting and diarrhoea among the most common. Those effects do not scale down neatly in step with an unmeasured reduction.

An inaccurately measured dose may not provide the expected treatment benefit, and side effects can still occur. Because the amount delivered is uncertain, it is not possible to predict reliably how effective or tolerable this approach will be. Follow the prescribed dosing instructions and speak to your prescriber if side effects or cost are making treatment difficult to continue.

The tolerance structure breaks

Dose escalation exists to build tolerance in stages, so that each step is manageable because of the weeks spent below it.Wegovy's dose-escalation schedule is designed to help patients adjust to treatment gradually. Taking irregular or unmeasured doses can make treatment response and tolerability less predictable. If you have changed your dosing pattern or interrupted treatment, ask your prescriber how to proceed rather than restarting or increasing the dose yourself.

You lose the ability to tell what is working

If your dose is unknown and inconsistent, nothing you observe tells you anything useful. Weight not moving could be the dose, the method, or the treatment genuinely not suiting you, and there is no way to distinguish them.

NICE frames the six month point as a genuine review, considering whether to continue if less than 5% of initial weight has been lost on the highest tolerated dose. That review is meaningless if nobody knows what dose you were actually on.

If the format rather than the medicine is part of what makes treatment hard to sustain, that is worth raising too. The oral GLP-1 route is a different licensed medicine rather than a workaround, and it is a legitimate thing to ask about.

How many doses are in a pen?

The number of prescribed doses depends on the specific Wegovy pen. The UK FlexTouch pens used for doses up to 2.4 mg contain four prescribed doses, but some solution may remain after the fourth injection. This leftover solution is not an additional dose and should not be used to calculate extra injections. Always follow the instructions supplied with your particular pen.

Compounded and unlicensed GLP-1 products

This is where the genuine danger sits, and it deserves more attention than the click charts do.

What the MHRA says

The MHRA is direct about products obtained outside the prescription route. It warns that such products may not contain the GLP-1 medicine you think you are buying, and could be contaminated with bacteria and other harmful substances.

It also states that products without UK authorisation have not been tested for safety, quality or effectiveness, and that there is no assurance they contain what they claim to at all. Anyone selling an unauthorised product in the UK is doing so illegally.

Its practical advice is as simple as safety advice gets: if you are offered a GLP-1 medicine without needing a prescription, walk away. It also advises checking that the pharmacy is registered with the General Pharmaceutical Council.

The verification test

The reason unlicensed products are so hard to assess is that there is nothing to assess them against. With a licensed medicine, the regulator has examined the evidence, the manufacturing and the safety profile before it reaches you, and an approved leaflet tells you what is in it.

Unlicensed GLP-1 products may not have undergone the regulatory assessment required for an authorised medicine. Their composition, quality, safety and effectiveness may therefore be uncertain. Buying medicines from unverified sellers also increases the risk of receiving counterfeit, contaminated or incorrectly labelled products. Use a registered pharmacy and an appropriate prescription route.

Why these medicines cost what they do

Treatment in this class is a prescription medicine supplied through a regulated route, which carries real costs: the medicine itself, the pharmacy, the prescriber's time, cold chain storage and delivery, and the ongoing review that makes it safe.

Monthly cost varies with the dose you are on and the provider you use, which is why a figure quoted in one place will not match another.

How to compare cost honestly

The single most useful habit is to compare across twelve months rather than looking at a first month figure. Introductory pricing is common, doses change over time, and a low entry point can sit in front of a considerably higher ongoing cost.

Work out what a full year looks like at the dose you are likely to settle on, including consultation and delivery, and compare that figure across options. Also check what is included: whether reviews are charged separately, whether you can contact a prescriber between reviews, and what happens if you need to pause.

And verify the basics before anything else. A legitimate service requires a consultation, is dispensed by a GPhC registered pharmacy, and supplies the approved patient information leaflet with your medicine.

If you are struggling to afford treatment

This is the actual subject of this page, and it deserves a straight answer rather than sympathy.

Tell your prescriber

People routinely do not, because it feels like a conversation about money rather than medicine. It is not. Affordability is a clinical issue, because a plan you cannot sustain is a plan that fails, and a prescriber cannot work around a constraint they do not know exists.

Say it plainly at your review: this is becoming difficult to afford, what are my options. That sentence opens several doors. Stretching a pen in silence closes all of them.

What a prescriber can actually do

• Review whether the dose you are on is the one you need, since your highest tolerated dose is not necessarily the highest dose available.
• Consider whether a different licensed medicine or format suits you.
• Discuss whether now is the right time to continue, pause or stop with a proper plan.
• Make sure you are not paying for treatment that is not working, which the six month review exists to establish.

Stopping properly, rather than stretching badly

If treatment has to end for now, ending it deliberately is a genuinely different outcome from letting it degrade into unmeasured doses.

NICE advises that support to help maintain weight loss should be offered to people who are stopping weight management medicines, and recognises that overweight and obesity can be a long term health issue with relapses being normal. A planned stop with support if you stop in place protects more of what you have achieved than a slow, improvised decline.

If you have already been stretching doses

If you have been changing your Wegovy dose by counting clicks or stretching injections, contact your prescriber or pharmacist for advice before making further dose changes. Explain how you have been using the pen and when you last injected. They can advise you on the safest next step, including whether your treatment schedule needs to be adjusted.

It matters clinically for two reasons. Your prescriber is currently making decisions based on a dose they believe you have been taking, which means their judgement about whether treatment is working is based on the wrong information. And returning to a full dose after a period of irregular, unmeasured dosing may be less comfortable than it was before, which is something they can plan around if they know.

Nobody will be interested in telling you off. Services that treat this as a character failure rather than a practical problem are not doing the job properly. What a prescriber needs is an accurate picture, and what you need is a plan you can actually afford to follow.

Taking a lower dose than prescribed: the legitimate version

There is a proper way to be on a lower dose, and it is worth knowing that it exists.

If you are struggling with side effects or tolerability, your prescriber can review your treatment and decide whether a delay in dose escalation, a dose adjustment or another approach is appropriate under the product information and your clinical circumstances. Do not assume that remaining on a lower dose indefinitely is suitable; this requires an individual review.

The difference between that and stretching a pen is not strictness. It is that one produces a known dose that somebody is accountable for, and the other produces an unknown dose that nobody is.

What to do instead

1. Stop looking for a click chart. It is not a shortcut you have found, it is a risk somebody else is taking with your treatment.
2. Book or request a review and say that cost is the issue, in those words.
3. Ask about the dose you are actually on, and whether a lower step would still work for you.
4. Ask about other licensed options, including different formats.
5. Compare total cost over a year, not a first month figure, if you are looking at options.
6. If treatment has to pause, plan the pause. A deliberate stop with support keeps more of the result than a gradual improvised one.
7. Never buy from anywhere that does not require a prescription, whatever the price.

Medical Disclaimer

This article is general information about prescription only medicines and is not medical advice. It contains no dosing instructions, no dose escalation schedule and no method for altering a prescribed dose, and it is not a substitute for a consultation with a qualified healthcare professional. These medicines should only be used under the supervision of an appropriately qualified prescriber, at the dose prescribed, and in line with the approved patient information leaflet supplied with your medicine.

Treatment suitability depends on an individual clinical assessment, and results vary between individuals. Never alter a prescribed dose yourself. Seek urgent medical attention for severe or persistent abdominal pain, repeated vomiting, sudden changes in vision, or signs of an allergic reaction such as swelling of the face, lips or throat or difficulty breathing. Suspected side effects can be reported through the MHRA Yellow Card scheme.